Rameda Pharmaceuticals

www.ramedapharma.com

Our Vision: To become the most valuable emerging pharmaceutical company in Egypt. Our Mission: To provide our customers quality health care solutions in a cost effective manner by developing products and services that satisfy their health requirements. Establishment Rameda began operations in 1994 and was established by a group of Gulf investors with the intention of creating one of the largest pharmaceutical operations in the region. Owners hired V-Konsult of Germany to create a state-of-the art design. Contracted British Carter Construction company to build the Rameda’s facilities. Partnership with Alcon In 1999, Rameda entered into an agreement with Alcon to manufacture – under license - their ophthalmology products. In order to guarantee the quality of their products, Alcon built one of the highest quality eye production facilities in the region at Rameda. Quality enhancement Rameda renewed the syrup production to become GMP (Good Manufacturing Practice). A new Beginning In 2011, Compass Capital led a consortium of private equity investors for the acquisition of 100% of Rameda. Compass Capital plans to establish Rameda as a regional leader in the industry. To execute this strategy Rameda hired a new management team with a proven track record to complement the existing team. Company has commissioned M+W Group to transform solid dosage and beta lactam areas into GMP. Brining entire facility to compliance.

Read more

Reach decision makers at Rameda Pharmaceuticals

Lusha Magic

Free credit every month!

Our Vision: To become the most valuable emerging pharmaceutical company in Egypt. Our Mission: To provide our customers quality health care solutions in a cost effective manner by developing products and services that satisfy their health requirements. Establishment Rameda began operations in 1994 and was established by a group of Gulf investors with the intention of creating one of the largest pharmaceutical operations in the region. Owners hired V-Konsult of Germany to create a state-of-the art design. Contracted British Carter Construction company to build the Rameda’s facilities. Partnership with Alcon In 1999, Rameda entered into an agreement with Alcon to manufacture – under license - their ophthalmology products. In order to guarantee the quality of their products, Alcon built one of the highest quality eye production facilities in the region at Rameda. Quality enhancement Rameda renewed the syrup production to become GMP (Good Manufacturing Practice). A new Beginning In 2011, Compass Capital led a consortium of private equity investors for the acquisition of 100% of Rameda. Compass Capital plans to establish Rameda as a regional leader in the industry. To execute this strategy Rameda hired a new management team with a proven track record to complement the existing team. Company has commissioned M+W Group to transform solid dosage and beta lactam areas into GMP. Brining entire facility to compliance.

Read more
icon

Country

icon

City (Headquarters)

Giza

icon

Employees

501-1000

icon

Founded

1994

icon

Estimated Revenue

$1 to $1,000,000

icon

Social

  • icon

Employees statistics

View all employees

Potential Decision Makers

  • Chief Executive Officer and Board Member

    Email ****** @****.com
    Phone (***) ****-****
  • Internal Audit , Risk Management , and Compliance Director

    Email ****** @****.com
    Phone (***) ****-****
  • Franchise Manager ( Gyne and Nephrology )

    Email ****** @****.com
    Phone (***) ****-****
  • Business Unit Manager

    Email ****** @****.com
    Phone (***) ****-****

Technologies

(19)

Reach decision makers at Rameda Pharmaceuticals

Free credits every month!

My account

Sign up now to uncover all the contact details